| Autoantibody response to ZRF1 and KRR1 SEREX antigens in patients with breast tumors of different histological types and grades L Dyachenko, K Havrysh, A Lytovchenko, I Dosenko, S Antoniuk, ... Disease markers 2016, 2016 | 12 | 2016 |
| Physcion enhances sensitivity of pancreatic adenocarcinoma and lung carcinoma cell lines to cisplatin DV Savenkova, КV Havrysh, VS Skripova, NE Ionova, AK Nurgalieva, ... BioNanoScience 10, 549-553, 2020 | 3 | 2020 |
| Evaluation of RAD50 as a prognostic marker of survival in breast cancer patients KV Havrysh, VV Filonenko, IG Serebriiskii, RG Kiyamova Annals of Oncology 27, vi33, 2016 | 3 | 2016 |
| XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients KV Havrysh, M Bogdanov, AK Nurgalieva, R Kiyamova Annals of Oncology 30, ix128, 2019 | 1 | 2019 |
| PLSCR1 and XKR8: New markers for low-grade glioma progression and outcome KV Havrysh, M Bogdanov, R Kiyamova Annals of Oncology 30, vii15, 2019 | 1 | 2019 |
| New potential biomarkers for breast cancer prognosis K Havrysh, R Kiyamova Annals of Oncology 28, vii6, 2017 | 1 | 2017 |
| SLC34A2 as a potential prognostic marker of triple-negative breast cancer patients' survival K Havrysh, SV Petrov, GZ Mukhametshina, RG Kiyamova HUMAN GENE THERAPY 30 (11), A65-A65, 2019 | | 2019 |
| The combined action of cisplatin and Physcion increases the ROS level in the lung and pancreas cancer cells DV Savenkova, K Havrysh, VS Skripova, AK Nurgalieva, LF Minigulova, ... HUMAN GENE THERAPY 30 (11), A62-A62, 2019 | | 2019 |
| Silencing of the RAD50 gene contributes to enhancing the sensitivity of the triple-negative breast cancer cells to carboplatin KV Havrysh, MV Bogdanov, RG Kiyamova Cancer Research 79 (13_Supplement), 4927-4927, 2019 | | 2019 |
| Нокдаун гена RAD50 сенсибилизирует раковые клетки молочной железы трижды-негативного подтипа к карбоплатину К Гавриш, А Нургалиева, Л Минигулова, Д Савенкова, В Скрипова, ... Фундаментальная и клиническая онкология: достижения и перспективы развития …, 2019 | | 2019 |
| Candidate markers of homologous recombination deficiency for triple negative breast cancer KV Havrysh, G Mukhametshina, S Petrov, S Safina, R Kiyamova Annals of Oncology 29, ix119-ix120, 2018 | | 2018 |
| Investigation of the combined action of cisplatin and 6-phosphogluconate dehydrogenase inhibitor on pancreatic and lung cancer cell lines DV Savenkova, LF Minigulova, KV Havrysh, VS Skripova, RG Kiyamova Annals of Oncology 29, vi5, 2018 | | 2018 |
| Potential prognostic markers for recurrence and survival in triple-negative breast cancer KV Havrysh, G Mukhametshina, S Safina, S Petrov, RG Kiyamova Annals of Oncology 29, vi16, 2018 | | 2018 |
| The effect of small molecule compounds Physcion and PFI-3 on the sensitivity of the tumor cell lines SCC61 and AcPC-1 to cisplatin D Savenkova, L Minigulova, K Havrysh, V Skripova, I Serebriiskii, ... EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 48, 220-221, 2018 | | 2018 |
| rAd50, A potentiAl prediCtive MArker of CheMotherApy resistAnCe K HAVRYSH, V FILONENKO, R KIYAMOVA | | |
Ramziya KiyamovaDepartment of Biochemistry, Biotechnology, and Pharmacology, Institute of Fundamental Medicine and Biology, Kazan Federal UniversityVerified email at kpfu.ru
